CYP2D6 gene resequencing in the Malagasy, a population at the crossroads between Asia and Africa: a pilot study

Pharmacogenomics. 2022 Apr;23(5):315-325. doi: 10.2217/pgs-2021-0146. Epub 2022 Mar 1.

Abstract

Background:Plasmodium vivax malaria is endemic in Madagascar, where populations have genetic inheritance from Southeast Asia and East Africa. Primaquine, a drug of choice for vivax malaria, is metabolized principally via CYP2D6. CYP2D6 variation was characterized by locus-specific gene sequencing and was compared with TaqMan™ genotype data. Materials & methods: Long-range PCR amplicons were generated from 96 Malagasy samples and subjected to next-generation sequencing. Results: The authors observed high concordance between TaqMan™-based CYP2D6 genotype calls and the base calls from sequencing. In addition, there are new variants and haplotypes present in the Malagasy. Conclusion: Sequencing unique admixed populations provides more detailed and accurate insights regarding CYP2D6 variability, which may help optimize primaquine treatment across human genetic diversity.

Keywords: CYP2D6; Madagascar; Plasmodium vivax; malaria treatment; next-generation sequencing; primaquine.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Africa
  • Antimalarials* / therapeutic use
  • Asia
  • Cytochrome P-450 CYP2D6* / genetics
  • Cytochrome P-450 CYP2D6* / metabolism
  • Humans
  • Pilot Projects
  • Primaquine / therapeutic use

Substances

  • Antimalarials
  • Cytochrome P-450 CYP2D6
  • Primaquine